BioTeSys' colleagues regularly appears as speaker at public events and publish scientific articles. Information on those events and release notes, as well as company announcements can be found here at a glance.
The Analytics Department of the BioTeSys GmbH offers the determination of enzyme activities of neutral lactase activity (NLU) and arylsulfatase (ASU). The validation of the used method is verified by an interlaboratory exchange test including the laboratory DSM Food Specialties.
The BioTeSys GmbH receives the accreditation as research service provider from the French Ministry of Higher Education and Research which enables French companies to claim research efforts as tax deductions. French customers of BioTeSys benefit from the accreditation with a tax relief up to 30 percent of the contract value of the R&D project (Dépenses de recherche).
L'entreprise BioTeSys S.a.r.l. a été accréditée par le Ministère de l'Educa-tion Nationale de l'Enseignement Supérieur et de la Recherche comme prestataire de services en R & D (recherche et développement). Les clients français de BioTeSys pourront bénéficier d’un allègement fiscal allant jusqu'à 30% des dépenses en recherche et développement engagées dans le cadre de leur projet.
Not only BioTeSys contemplate about valid scientific evidendence for EFSA applications.
Information about the SOP's used within the Mark-Age project: "Mark-Age standard operating procedures (SOPs): A successful effort."
Further releases on the EU research project about the biological age of men: "Mark-Age biomarkers of ageing."
A pan-European team of scientists identifies the markers of the biological age in humans using state-of-the-art methods. The first project releases from BioTeSys and the other 25 working groups at universities, national research centers and companies from 14 European countries are now freely accessible: "Mark-Age biomarkers of ageing."
Jürgen Bernhardt, CEO BioTeSys, publishes with collegues in the latest edition of Nutrafoods "Joint health: What degree of evidence is necessary to support health claims for food supplements, taking glucosamine as an example?"
BioTeSys proclaims that clinical trials with nutritions do not have the same requierements as clinical studies with pharmaceuticals. Only a specialised company can fulfill those requierements
BENEO-Orafti S.A. has gained a positive EFSA evaluation for its prebiotic fibre inulin improving the effect on bowel function by increasing stool frequency without triggering diarrhoea. EFSA’s decision is based on six human intervention studies. The study conducted by BioTeSys – Nutritional CRO (Schulz et al., 2012, unpublished) was used to establish the conditions of use for this health claim.